Jpmorgan Chase & CO Blueprint Medicines Corp Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,155,634 shares of BPMC stock, worth $103 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,155,634
Previous 1,222,052 5.43%
Holding current value
$103 Million
Previous $113 Million 10.79%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$82.48 - $101.39 $5.48 Million - $6.73 Million
-66,418 Reduced 5.43%
1,155,634 $101 Million
Q3 2024

Dec 26, 2024
SELL
$84.1 - $120.5 $218,828 - $313,541
-2,602 Reduced 0.21%
1,222,052 $113 Million
Q3 2024

Nov 08, 2024
SELL
$84.1 - $120.5 $218,828 - $313,541
-2,602 Reduced 0.21%
1,222,052 $113 Million
Q2 2024

Dec 26, 2024
BUY
$85.18 - $108.78 $221,638 - $283,045
2,602 Added 0.21%
1,224,654 $132 Million
Q2 2024

Aug 12, 2024
SELL
$85.18 - $108.78 $7.39 Million - $9.43 Million
-86,718 Reduced 6.61%
1,224,654 $132 Million
Q1 2024

Dec 26, 2024
BUY
$73.17 - $99.79 $6.54 Million - $8.91 Million
89,320 Added 7.31%
1,311,372 $124 Million
Q1 2024

May 10, 2024
SELL
$73.17 - $99.79 $15.2 Million - $20.8 Million
-208,336 Reduced 13.71%
1,311,372 $124 Million
Q4 2023

Dec 26, 2024
BUY
$43.96 - $92.84 $13.1 Million - $27.6 Million
297,656 Added 24.36%
1,519,708 $140 Million
Q4 2023

Feb 12, 2024
SELL
$43.96 - $92.84 $7.67 Million - $16.2 Million
-174,509 Reduced 10.3%
1,519,708 $140 Million
Q3 2023

Nov 14, 2023
BUY
$46.9 - $66.0 $4.02 Million - $5.65 Million
85,648 Added 5.32%
1,694,217 $85.1 Million
Q2 2023

Aug 11, 2023
BUY
$42.2 - $66.37 $2.4 Million - $3.77 Million
56,813 Added 3.66%
1,608,569 $102 Million
Q1 2023

May 18, 2023
BUY
$37.97 - $50.0 $3.01 Million - $3.96 Million
79,216 Added 5.38%
1,551,756 $69.8 Million
Q1 2023

May 11, 2023
BUY
$37.97 - $50.0 $923,620 - $1.22 Million
24,325 Added 1.68%
1,472,540 $66.2 Million
Q4 2022

Feb 13, 2023
SELL
$41.06 - $66.48 $1.74 Million - $2.82 Million
-42,419 Reduced 2.85%
1,448,215 $63.4 Million
Q3 2022

Nov 14, 2022
SELL
$49.93 - $77.7 $11.7 Million - $18.2 Million
-233,856 Reduced 13.56%
1,490,634 $98.2 Million
Q2 2022

Aug 11, 2022
BUY
$45.23 - $70.15 $2.23 Million - $3.46 Million
49,366 Added 2.95%
1,724,490 $87.1 Million
Q1 2022

May 11, 2022
BUY
$54.1 - $110.08 $1.68 Million - $3.41 Million
30,963 Added 1.88%
1,675,124 $107 Million
Q4 2021

Feb 10, 2022
BUY
$94.25 - $115.99 $11.9 Million - $14.7 Million
126,350 Added 8.32%
1,644,161 $176 Million
Q3 2021

Nov 12, 2021
BUY
$80.98 - $109.47 $123 Million - $166 Million
1,517,811 New
1,517,811 $156 Million

Others Institutions Holding BPMC

# of Institutions
380
Shares Held
65.9M
Call Options Held
1.6M
Put Options Held
1.41M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.3B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email